Analysis of the Association of Matrix Metalloproteinase-1 Gene Promoter (rs1799750) Polymorphism and Risk of Ovarian Cancer

Abstract

ObjectiveStudies investigating the association betweenmatrix metalloproteinase-1(MMP1) gene promoter 1607–base pair (bp) polymorphism and ovarian cancer risk have yielded conflicting results.MethodsWe therefore carried out a meta-analysis of 754 ovarian cancer cases and 1184 controls from 5 published case-control studies. The strength of the association betweenMMP11607-bp polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs).ResultsThe results suggest that no statistically significant associations exist betweenMMP11607-bp polymorphisms and ovarian cancer risk in all 4 genetic models (2G2G vs 1G1G: OR, 1.08; 95% CI, 0.81–1.43;P= 0.23; 1G2G vs 1G1G: OR, 1.06; 95% CI, 0.82–1.36;P= 0.15; 1G2G + 2G2G vs 1G1G: OR, 1.05; 95% CI, 0.83–1.34;P= 0.16; 2G2G vs 1G1G + 1G2G: OR, 0.98; 95% CI, 0.80–1.20;P= 0.84).ConclusionsIn summary, this meta-analysis showed that theMMP11607-bp polymorphism is not associated with ovarian cancer risk.